FRANKLIN, Mass. — Cohesive Technologies Inc.
(http://www.cohesivetech.com), developers of TurboFlow(R), a technology for high
throughput liquid chromatography systems, announced today that it has entered
into a development, sales, and support agreement with Applied Biosystems Group
(NYSE: ABI), an Applera Corporation business. The agreement covers LC/MS/MS
systems jointly developed by Applied Biosystems and MDS Inc. (Toronto: MDS,
NYSE: MDZ), through its Applied Biosystems/MDS Sciex instrument partnership, a
supplier of mass spectrometers and other analytical instrumentation.
Because the companies have complementary products and technologies, this
agreement allows Cohesive and Applied Biosystems to jointly provide their
customers with a complete, seamless, integrated, high throughput system for
bioanalysis in drug development. Cohesive’s patented chromatography systems,
offering increased productivity and throughput, sample prep elimination, and
high sensitivity, will be integrated with the Applied Biosystems/MDS Sciex
product line of highly sensitive mass spectrometers.
Under this agreement, Cohesive Technologies and Applied Biosystems agree
to broaden their collaboration on joint system development, including
modifying software to provide seamless management and single point control of
all system functions, and developing new applications for the combined
“Our industry leading technology and recently expanded strategic
collaboration with Applied Biosystems enables us to build on our combined
strength in bioanalysis, and provides an opportunity to integrate liquid
chromatography/mass spectrometry systems closer than ever before for our
customers,” said Peter H. Glick, President and CEO of Cohesive Technologies.
“We look forward to continuing our strong collaboration with Applied
Biosystems to maximize the significant opportunities that our companies’
Cohesive Technologies develops, manufactures, and markets novel liquid
chromatography systems and chemistries for the pharmaceutical and
biotechnology marketplace. Cohesive’s high throughput liquid chromatography
systems have been shown to dramatically increase speed and reduce costs of
bioanalytical testing for drug discovery and development. Researchers at
dozens of major pharmaceutical and biotechnology companies have published
results indicating up to a four-fold increase in sample throughput using
Cohesive’s multiplexing and patented TurboFlow(R) technologies. The Company
has over 300 systems installed worldwide.